DexCom (NASDAQ:DXCM) Given New $450.00 Price Target at Raymond James

DexCom (NASDAQ:DXCM) had its target price hoisted by Raymond James from $395.00 to $450.00 in a report issued on Wednesday morning, The Fly reports. Raymond James currently has an outperform rating on the medical device company’s stock.

A number of other equities research analysts also recently issued reports on the company. Cowen increased their price objective on DexCom from $430.00 to $450.00 and gave the stock an outperform rating in a research report on Tuesday, July 7th. Robert W. Baird increased their price objective on DexCom from $296.00 to $373.00 and gave the stock an outperform rating in a research report on Wednesday, April 29th. SVB Leerink increased their price objective on DexCom from $465.00 to $485.00 and gave the stock an outperform rating in a research report on Wednesday. BidaskClub upgraded DexCom from a buy rating to a strong-buy rating in a research report on Wednesday, July 22nd. Finally, Citigroup raised their price target on DexCom from $440.00 to $485.00 and gave the company a buy rating in a research report on Wednesday. Seven investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $394.95.

DexCom stock opened at $435.54 on Wednesday. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.58 and a quick ratio of 5.41. DexCom has a one year low of $138.28 and a one year high of $446.50. The firm has a market capitalization of $41.70 billion, a P/E ratio of 198.88, a PEG ratio of 4.74 and a beta of 0.79. The business has a fifty day moving average price of $410.52 and a 200-day moving average price of $325.07.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, July 28th. The medical device company reported $0.79 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.48. DexCom had a return on equity of 29.01% and a net margin of 11.93%. The company had revenue of $451.80 million for the quarter, compared to the consensus estimate of $415.21 million. During the same quarter last year, the business posted $0.08 earnings per share. The firm’s revenue was up 34.3% compared to the same quarter last year. Sell-side analysts expect that DexCom will post 2.45 earnings per share for the current fiscal year.

In related news, CEO Kevin R. Sayer sold 6,000 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $344.63, for a total value of $2,067,780.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Shelly Ramasamy Selvaraj sold 400 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $404.05, for a total value of $161,620.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 63,293 shares of company stock worth $24,266,963. Company insiders own 0.69% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sunbelt Securities Inc. bought a new stake in shares of DexCom in the fourth quarter worth about $3,062,000. Cognios Capital LLC bought a new stake in shares of DexCom in the first quarter worth about $26,000. Nvwm LLC bought a new stake in shares of DexCom in the first quarter worth about $27,000. Duncker Streett & Co. Inc. bought a new stake in shares of DexCom in the second quarter worth about $41,000. Finally, Weaver Consulting Group bought a new stake in DexCom during the 1st quarter valued at approximately $27,000. 97.08% of the stock is currently owned by institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Recommended Story: Derivative

The Fly

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.